Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone

(2012) A. L. Godfrey et al.   BLOOD

COLD-PCR and Innovative Microarray Substrates for Detecting and Genotyping MPL Exon 10 W515 Substitutions

(2012) A. Brisci et al.   CLINICAL CHEMISTRY

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

(2012) S. Schnittger et al.   HAEMATOLOGICA

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

(2012) Roberto Marchioli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm

(2011) Elisa Rumi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms

(2011) D. Pietra et al.   HAEMATOLOGICA

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients

(2011) A Pardanani et al.   LEUKEMIA

In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes

(2011) Alessandra Balduini et al.   PLoS One

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms

(2010) A. V. Jones et al.   BLOOD

Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies

(2010) C. O'Keefe et al.   BLOOD

Clinical utility of routineMPLexon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis

(2010) Elaine M. Boyd et al.   BRITISH JOURNAL OF HAEMATOLOGY

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

(2009) L. Malcovati et al.   BLOOD

Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor

(2009) C. Pecquet et al.   BLOOD

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

(2009) F. H. Grand et al.   BLOOD

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

(2008) A. M. Vannucchi et al.   BLOOD

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

(2008) P. A. Beer et al.   BLOOD

UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation

(2008) H Szpurka et al.   LEUKEMIA

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

(2008) R Chaligné et al.   LEUKEMIA